Cargando…
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to Apr...
Autores principales: | Dal, Mehmet Sinan, Ulu, Bahar Uncu, Uzay, Ant, Akay, Olga Meltem, Beşışık, Sevgi, Yenerel, Mustafa Nuri, Çelik, Serhat, Kaynar, Leylagül, Yücel, Orhan Kemal, Deveci, Burak, Sönmez, Mehmet, Mehtap, Özgür, Beköz, Hüseyin Saffet, Sunu, Cenk, Salim, Ozan, Ulaş, Turgay, Kartı, Sami, Altuntaş, Fevzi, Ferhanoğlu, Burhan, Tuğlular, Tülin Fırat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676783/ https://www.ncbi.nlm.nih.gov/pubmed/36401621 http://dx.doi.org/10.1007/s00277-022-05052-x |
Ejemplares similares
-
P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY
por: Dal, M. S., et al.
Publicado: (2022) -
Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020) -
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022) -
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022) -
Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)